Disabling the CD161 pathway restores the T-cell's ability to attack gliomas and extends lifespan in animal models of brain cancer.
Glioma patients whose tumors were hypermutated showed no significant benefit when treated with checkpoint blockers.
Latest
Dana-Faber Cancer Institute
